105956-99-8

Basic information

• Product Name: Clinafloxacin hydrochloride
• Synonyms: CLINAFLOXACIN HCL;CLINANFLOXACIN HYDROCHLORIDE;Clinafloxacinhydrochloride;7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride;7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-keto-quinoline-3-carboxylic acid hydrochloride;7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid hydrochloride;7-(3-azanylpyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid hydrochloride;3-Quinolinecarboxylic acid, 7-(3-aMino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
• CAS NO: 105956-99-8
• Molecular Formula: C17H18Cl2FN3O3
• Molecular Weight: 402.25
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API
• Mol File: 105956-99-8.mol
• Article Data: 1

Chemical Properties

• Melting Point: 162-168°C
• Boiling Point: 592.3 °C at 760 mmHg
• Flash Point: 312 °C
• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly, Heated)
• Stability: Hygroscopic
• CAS DataBase Reference: Clinafloxacin hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Clinafloxacin hydrochloride(105956-99-8)
• EPA Substance Registry System: Clinafloxacin hydrochloride(105956-99-8)

Safety Data

• Hazardous Substances Data: 105956-99-8(Hazardous Substances Data)

Usage

Description

Clinafloxacin hydrochloride is a new fluoroquinolone antimicrobial agent, characterized by its pale yellow solid appearance. It is a potent intraphagocytic bactericidal agent, effective against both gram-positive and gram-negative bacteria, making it a valuable addition to the arsenal of antibiotics in the fight against bacterial infections.

Uses

Used in Pharmaceutical Industry:
Clinafloxacin hydrochloride is used as an antibacterial agent for the treatment of various bacterial infections. Its broad-spectrum activity against gram-positive and gram-negative bacteria makes it a versatile choice for targeting a wide range of bacterial pathogens.
Used in Research and Development:
In the field of medical research, Clinafloxacin hydrochloride serves as a valuable compound for studying the mechanisms of bacterial resistance and the development of new strategies to combat antibiotic resistance. Its unique properties can also be explored for the creation of novel drug delivery systems or combination therapies to enhance its efficacy and minimize the risk of resistance development.
Used in Hospital Settings:
Clinafloxacin hydrochloride is utilized in hospitals and other healthcare facilities as a potent antibiotic for the treatment of severe bacterial infections that may not respond to other available treatments. Its effectiveness against a wide range of bacteria makes it a crucial tool in the management of complex and life-threatening infections.

Biological Activity

clinafloxacin is a broad-spectrum antibiotic of the quinolone carboxylic acid category that inhibits both dna gyrase and topoisomerase iv dually in streptococcus pneumonia. clinafloxacin, a fluoroquinolone, is currently in development for oral and intravenous therapy of serious infections.in selected volunteer subjects and patients, after the administration of oral and intravenous doses of racemic drug, the clinafloxacin showed a broad-spectrum antibiotic of the quinolone carboxylic acid category. the absorption of the clinafloxacin enantiomer was rapid after oral 400 mg dose and 400 mg intravenous dose of racemic drug [1]. clinafloxacin showed high activity against s. pneumoniae 7785 with the mic value of 0.125 μg/ml. clinafloxacin showed potent broad-spectrum in vitro activity against gram-positive, gram-negative, and anaerobic pathogens [2]. clinafloxacin has been identified as the most active fluoroquinolone against s. pneumoniae compared to grepafloxacin, levofloxacin, ofloxacin, sparfloxacin, and trovafloxacin and is currently being evaluated as an antipneumococcal agent [3].

references

[1]. humphrey g h, shapiro m a, randinitis e j, et al. pharmacokinetics of clinafloxacin enantiomers in humans[j]. the journal of clinical pharmacology, 1999, 39(11): 1143-1150.[2]. pan x s, fisher l m. dna gyrase and topoisomerase iv are dual targets of clinafloxacin action in streptococcus pneumoniae[j]. antimicrobial agents and chemotherapy, 1998, 42(11): 2810-2816.[3]. jorgensen j h, weigel l m, swenson j m, et al. activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant streptococcus pneumoniae[j]. antimicrobial agents and chemotherapy, 2000, 44(11): 2962-2968.

InChI:InChI=1/C17H17ClFN3O3.ClH/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9;/h5,7-9H,1-4,6,20H2,(H,24,25);1H

Relevant articles and documents

Preparation of 7-(3-amino- and 3-amino-methyl-1-pyrrolidinyl)-3-quinolonecarboxylic acids and -naphthyridonecarboxylic acids

Process for the preparation of antibacterial compounds of the formula STR1 comprises condensing an oxo compound of the formula STR2 with an amino compound of the formula STR3 to produce a compound of the formula STR4 reacting the compound of the formula (III) with a compound of the formula STR5 to give a compound of the formula STR6 and then eliminating the amino-protective group STR7